[Form 4] NAYA Biosciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Matthew K. Szot, a director of INVO Fertility, Inc. (IVF), reported transactions on Form 4 showing an option exercise and a small disposition. On 08/26/2025 Mr. Szot exercised a stock option with a $1.01 exercise price to purchase 45,000 shares of common stock, and following that transaction he beneficially owned 45,164 shares. The option vests in four equal installments beginning the first day of the calendar quarter after 08/26/2025 and quarterly thereafter until fully vested. The filing also reports a disposition of 56 shares of common stock. The Form 4 is signed and dated 08/28/2025.

Positive

• Director exercised 45,000 option shares, converting potential equity into 45,000 common shares and raising beneficial ownership to 45,164 shares
• Clear vesting schedule disclosed: vests in four equal quarterly installments beginning the first day of the calendar quarter after 08/26/2025

Negative

• Disposition of 56 shares was reported (though immaterial relative to the option exercise)

Insights

Securities Analyst

TL;DR: Director exercised options to acquire 45,000 shares, materially increasing his reported beneficial holding to 45,164 shares.

Exercise of a large option block by a director converts potential equity into outstanding shares, increasing insider stake and aligning pay with equity ownership. The exercised option price of $1.01 is explicit and the resulting ownership is disclosed as direct. The vesting schedule spreads future forfeiture risk over quarterly installments beginning after 08/26/2025, which affects the timing of further vesting-related disclosures. The small reported disposition of 56 shares is immaterial relative to the acquisition.

Corporate Governance Expert

TL;DR: Transaction is routine: option exercise by a director with standard quarterly vesting; disclosure is straightforward and compliant.

The Form 4 shows clear reporting of an option exercise and subsequent beneficial ownership. The vesting cadence (four equal quarterly installments beginning after the grant) suggests the award is time-based rather than performance-based. No amendments, pledges, or derivative holdings beyond the exercised option are reported. From a governance perspective, documentation and signature on 08/28/2025 indicate timely filing practices.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Szot Matthew K

(Last) (First) (Middle)

C/O INVO FERTILITY, INC.

5582 BROADCAST COURT

(Street)

SARASOTA FL 34240

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INVO Fertility, Inc. [ IVF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								56	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.01	08/26/2025		A		45,000		(1)	08/26/2035	Common Stock	45,000	$0	45,164	D

Explanation of Responses:

1. The option vests in four equal installments beginning on the first day of the calendar quarter following August 26, 2025 and on the first day of each calendar quarter thereafter until fully vested.

	/s/ Matthew Szot	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Matthew K. Szot report on the Form 4 for INVO Fertility (IVF)?

He reported exercising a stock option to acquire 45,000 common shares at an exercise price of $1.01, and a disposition of 56 shares; beneficial ownership after the transactions was 45,164 shares.

When were the transactions dated on the Form 4?

The transactions are dated 08/26/2025, and the Form 4 is signed on 08/28/2025.

What is the vesting schedule for the exercised option reported by the director?

The option vests in four equal installments beginning on the first day of the calendar quarter following 08/26/2025 and on the first day of each calendar quarter thereafter until fully vested.

How many shares did the reporting person beneficially own after the reported transactions?

Following the reported exercise and disposition, the reporting person beneficially owned 45,164 shares of common stock.

What was the exercise price for the stock option exercised?

The conversion/exercise price of the reported stock option was $1.01.